140 related articles for article (PubMed ID: 9815763)
41. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
[TBL] [Abstract][Full Text] [Related]
42. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
Myers DE; Irvin JD; Smith RS; Kuebelbeck VM; Uckun FM
J Immunol Methods; 1991 Feb; 136(2):221-37. PubMed ID: 1705571
[TBL] [Abstract][Full Text] [Related]
43. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
44. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
[TBL] [Abstract][Full Text] [Related]
46. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
Vallera DA; Burns LJ; Frankel AE; Sicheneder AR; Gunther R; Gajl-Peczalska K; Pennell CA; Kersey JH
J Immunol Methods; 1996 Oct; 197(1-2):69-83. PubMed ID: 8890895
[TBL] [Abstract][Full Text] [Related]
47. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
48. Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide-linked pokeweed antiviral protein-antibody conjugates from blood.
Ramakrishnan S; Houston LL
Cancer Res; 1985 May; 45(5):2031-6. PubMed ID: 3986759
[TBL] [Abstract][Full Text] [Related]
49. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
Meany HJ; Seibel NL; Krailo M; Villaluna D; Chen Z; Gaynon P; Neglia JP; Park JR; Hutchinson R; Sato JK; Wells RJ; Woods WG; Reaman G
J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894
[TBL] [Abstract][Full Text] [Related]
50. Visualization of immunotoxin-mediated tumor cell death in vivo.
Erickson HA; Reinhardt RL; Hermanson JB; Panoskaltsis-Mortari A; Pennell CA
Clin Cancer Res; 2001 Mar; 7(3 Suppl):890s-894s. PubMed ID: 11300488
[TBL] [Abstract][Full Text] [Related]
51. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
52. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells.
Waddick KG; Myers DE; Gunther R; Chelstrom LM; Chandan-Langlie M; Irvin JD; Tumer N; Uckun FM
Blood; 1995 Dec; 86(11):4228-33. PubMed ID: 7492781
[TBL] [Abstract][Full Text] [Related]
53. Anti-HIV agents. TXU-PAP--early results.
TreatmentUpdate; 2000 Feb; 12(1):2. PubMed ID: 12125626
[No Abstract] [Full Text] [Related]
54. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
55. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
56. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
57. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Vey N; Giles FJ; Kantarjian H; Smith TL; Beran M; Jeha S
Clin Cancer Res; 2000 Feb; 6(2):731-6. PubMed ID: 10690560
[TBL] [Abstract][Full Text] [Related]
58. Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein.
Uckun FM; Ramakrishnan S; Houston LL
Cancer Res; 1985 Jan; 45(1):69-75. PubMed ID: 3871174
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
60. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE
Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
